Acorda misses on Q1 earnings, slashes expense guidance after restructuring

Shares in Acorda Therapeutics (NSDQ:ACOR) fell today after the biopharmaceutical company missed expectations on Wall Street with its 1st quarter results.

The Ardsley, N.Y.-based company posted a net loss of -$18.9 million, or -41¢ per share, on sales of $119.4 million for the 3 months ended March 31. In the same quarter last year, Acorda reported a net loss of -$0.5 million on sales of $115.9 million.

Get the full story at our sister site, Drug Delivery Business News.

The post Acorda misses on Q1 earnings, slashes expense guidance after restructuring appeared first on MassDevice.

from MassDevice http://ift.tt/2pD6hXC